Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC

Sponsor
Beckman Coulter, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04804306
Collaborator
(none)
198
1
9
22

Study Details

Study Description

Brief Summary

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).

Condition or Disease Intervention/Treatment Phase
  • Device: Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)

Detailed Description

The objective of this study is to develop a method for identifying sepsis patients from electronic health records (EHR) based on Sepsis-2 criteria. Sepsis patients will be identified using a Sepsis Definition which includes meeting SIRS score of ≥2 within 12 hours of ED presentation and any microbial testing ordered within 24 hours of ED presentation. The patient will be enrolled if it meets the Sepsis Definition and additional EMR data elements will be extracted to complete case report form. Furthermore, objectives include to confirm the clinical validity and performance of MDW in a control population of sepsis patients where MDW is measured but not reported to physicians. This study is an observational study which will simulate the decision impact of MDW on sepsis identification and patient management.

Study Design

Study Type:
Observational
Actual Enrollment :
198 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Post Market Clinical Utility of ESId (MDW Hematology Parameter) for Early Sepsis Detection in the Emergency Department (US Hospitals) - Hackensack University Medical Center
Actual Study Start Date :
Sep 5, 2021
Actual Primary Completion Date :
Jun 6, 2022
Actual Study Completion Date :
Jun 6, 2022

Arms and Interventions

Arm Intervention/Treatment
Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution

MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients

Device: Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
MDW measurement used to detect sepsis. Results will not be used to manage patients.

Outcome Measures

Primary Outcome Measures

  1. Potential reduction of Time to Antibiotics [Within 12 hours from presentation to the emergency department]

    MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated

Secondary Outcome Measures

  1. Performance [Within 12 hours from presentation to the emergency department]

    MDW's ability to identify Sepsis vs Non-Sepsis when using a Sepsis electronic medical record definition

Other Outcome Measures

  1. Health & Economic Benefits for Hospital Stay - Simulated [Within 12 hours from presentation to the emergency department]

    MDW's ability to reduce length of hospital stay

  2. Health & Economic Benefits for Intensive Care Unit Stay - Simulated [Within 12 hours from presentation to the emergency department]

    MDW's ability to reduce length of intensive care unit stay

  3. Health & Economic Benefits for Mortality - Simulated [Within 12 hours from presentation to the emergency department]

    MDW's ability to reduce in-house mortality

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 89 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Adult (18 to 89 years)

  • All race and ethnicities

  • Presenting to the emergency department with suspicion of infection

  • Whose assessment includes a CBC with differential

  • Meets EMR Sepsis Definition

Exclusion Criteria:
  • Pregnancy

  • Prisoners

  • Transfers from other ED

  • Previously enrolled

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hackensack University Medical Center Hackensack New Jersey United States 07601

Sponsors and Collaborators

  • Beckman Coulter, Inc.

Investigators

  • Principal Investigator: Joseph Parrillo, MD, Hackensack Meridian Health
  • Principal Investigator: Keri Bicking, PharmD, Hackensack Meridian Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beckman Coulter, Inc.
ClinicalTrials.gov Identifier:
NCT04804306
Other Study ID Numbers:
  • C01238
First Posted:
Mar 18, 2021
Last Update Posted:
Jul 18, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 18, 2022